Ash 2022 movers – Glycomimetics shakes off its sickle cell past
Meanwhile, there was bad blood between cell therapy players and their investors.
Not so fast for some accelerated approvals
The US conditional approval pathway has enjoyed years of expansion, but now the FDA is trying to put the toothpaste back into the tube.
Immunogen’s Mirasol trial goes down to the wire
Full data from mirvetuximab’s Soraya study make investors nervous as readout of the Mirasol confirmatory trial looms.
Sutro’s folate challenge to Immunogen hits a problem
In a battle of anti-folate receptor α projects STRO-002 outperforms mirvetuximab, but Sutro investors are not celebrating.
Biotech’s key fourth-quarter data
Deciphera, Allakos and Uniqure are all set for important data disclosures.
